The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
Francesco Caputo(University of Modena and Reggio Emilia), Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), Giulia Bertolini, Francesco Tovoli(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Valentina Massa(University of Milan), Ciro Celsa(Department of Health), Giuseppe Cabibbo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Alessandro Granito(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Fabio Piscaglia(Azienda USL di Bologna), Mario Scartozzi(University of Cagliari), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Giorgia Marisi, Caterina Stornello(CTO Andrea Alesini), Vincenzo Dadduzio(Istituto Oncologico Veneto), Stefano Cascinu(Vita-Salute San Raffaele University), Sabina Delcuratolo(Istituto Tumori Bari), Krisida Cerma(University of Modena and Reggio Emilia), Giorgio Astara(University of Cagliari), Sara Lonardi(Istituto Oncologico Veneto), Mario Domenico Rizzato(University of Padua), Fabio Conti, Marianna Silletta(Università Campus Bio-Medico), Nicola Silvestris(University of Messina), Caterina Vivaldi(Scuola Superiore Sant'Anna), Luca Faloppi(University of Macerata)
Cited by 47
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k